Skip to main content
TipRanks
Go Ultimate75% OFF

MaaT Pharma (MAAT) Stock Statistics & Valuation Metrics

4 Followers

Total Valuation

MaaT Pharma has a market cap or net worth of EUR 19.38M. The enterprise value is EUR 51.54M.

Market Cap
EUR 19.38M
Enterprise Value
EUR 51.54M

Share Statistics

MaaT Pharma has 18,856,394 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
18,856,394
Owned by Insiders
―
Owned by Institutions
0.50%

Financial Efficiency

MaaT Pharma’s return on equity (ROE) is -17.27 and return on invested capital (ROIC) is -101.22%.

Return on Equity (ROE)
-17.27
Return on Assets (ROA)
-0.70
Return on Invested Capital (ROIC)
-101.22%
Return on Capital Employed (ROCE)
-1.24
Revenue Per Employee
75.40K
Profits Per Employee
-517.68K
Employee Count
60
Asset Turnover
0.10
Inventory Turnover
37.32

Valuation Ratios

The current PE Ratio of MaaT Pharma is -0.54. MaaT Pharma’s PEG ratio is -0.05.

PE Ratio
-0.54
PS Ratio
6.09
PB Ratio
-1.19
Price to FCF
-1.20
Price to Operating Cash Flow
-1.23
PEG Ratio
-0.05

Income Statement

In the last 12 months, MaaT Pharma had revenue of 4.52M and earned -31.06M in profits. Earnings per share was -1.95.

Revenue
4.52M
Gross Profit
1.39M
Operating Income
-34.15M
Pretax Income
-34.85M
Net Income
-31.06M
EBITDA
-32.41M
Earnings Per Share (EPS)
-1.95

Cash Flow

In the last 12 months, operating cash flow was -15.71M and capital expenditures -454,000, giving a free cash flow of -16.16M billion.

Operating Cash Flow
-15.71M
Free Cash Flow
-16.16M
Free Cash Flow per Share
-0.86

Dividends & Yields

MaaT Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-83.53%
Earnings Yield
-176.98%

Stock Price Statistics

Beta
0.11
52-Week Price Change
-73.09%
50-Day Moving Average
1.30
200-Day Moving Average
3.81
Relative Strength Index (RSI)
40.15
Average Volume (3m)
103.40K

Important Dates

MaaT Pharma upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Sep 29, 2026
Next Earnings Date
Apr 01, 2027
Ex-Dividend Date
―

Financial Position

MaaT Pharma as a current ratio of 1.94, with Debt / Equity ratio of 969.43%

Current Ratio
1.94
Quick Ratio
1.94
Debt to Market Cap
0.18
Net Debt to EBITDA
0.23
Interest Coverage Ratio
-26.91

Taxes

In the past 12 months, MaaT Pharma has paid -3.79M in taxes.

Income Tax
-3.79M
Effective Tax Rate
0.11

Enterprise Valuation

MaaT Pharma EV to EBITDA ratio is -0.78, with an EV/FCF ratio of -1.61.

EV to Sales
8.19
EV to EBITDA
-0.78
EV to Free Cash Flow
-1.61
EV to Operating Cash Flow
-1.66

Balance Sheet

MaaT Pharma has EUR 17.10M in cash and marketable securities with EUR 23.78M in debt, giving a net cash position of -EUR 6.67M billion.

Cash & Marketable Securities
EUR 17.10M
Total Debt
EUR 23.78M
Net Cash
-EUR 6.67M
Net Cash Per Share
-EUR 0.35
Tangible Book Value Per Share
-EUR 0.91

Margins

Gross margin is 50.19%, with operating margin of -1195.06%, and net profit margin of -1080.20%.

Gross Margin
50.19%
Operating Margin
-1195.06%
Pretax Margin
-1127.33%
Net Profit Margin
-1080.20%
EBITDA Margin
-1045.34%
EBIT Margin
-1195.06%

Analyst Forecast

The average price target for MaaT Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-19.02%
EPS Growth Forecast
10.39%

Scores

Smart Score
―
AI Score
45